PUBLISHER: Acute Market Reports | PRODUCT CODE: 1383567
PUBLISHER: Acute Market Reports | PRODUCT CODE: 1383567
Lyme Disease Diagnostics Market - Growth, Future Prospects and Competitive Analysis, 2023 - 2031
The lyme disease diagnostics market plays a pivotal role in the early detection and treatment of Lyme disease, a vector-borne illness caused by the bacterium Borrelia burgdorferi. The lyme disease diagnostics market is expected to grow at a CAGR of 3.6% during the forecast period of 2023 to 2031, driven by the increasing incidence of Lyme disease, advancements in diagnostic technologies, and growing awareness. Despite the limitations in early-stage diagnosis, PCR tests are expected to lead in terms of CAGR. Geographic trends are shifting, with emerging hotspots in regions like Europe. Leading companies are focused on innovation, geographic expansion, and educational efforts to maintain their competitive edge in this dynamic market, ensuring timely and accurate diagnosis for Lyme disease patients.
Increasing Incidence of Lyme Disease
A primary driver of the lyme disease diagnostics market is the escalating incidence of Lyme disease, particularly in regions where ticks carrying Borrelia burgdorferi are prevalent. Evidence of this trend can be found in the rising number of reported Lyme disease cases globally. The disease's expansion into new geographic areas, driven by factors like climate change and increased outdoor activities, emphasizes the need for early and accurate diagnostics. This has led to a surge in demand for serological tests, polymerase chain reaction (PCR) tests, and other diagnostic methods for Lyme disease.
Advancements in Diagnostic Technologies
Advances in diagnostic technologies have significantly enhanced the lyme disease diagnostics market. Innovations in serological tests, PCR assays, and culture techniques have improved the accuracy and reliability of Lyme disease diagnosis. For example, the development of multiplex PCR assays enables simultaneous detection of multiple Borrelia species, contributing to more precise and timely diagnosis. Evidence of this progress can be seen in the increasing adoption of nucleic acid amplification tests (NAATs) for Lyme disease diagnosis, which offer superior sensitivity.
Growing Awareness and Early Detection Initiatives
The growing awareness of Lyme disease and initiatives to promote early detection have been instrumental in driving the market. Public health campaigns, healthcare provider education, and community outreach efforts emphasize the importance of recognizing early symptoms, such as erythema migrans (bull's-eye rash), and seeking a prompt diagnosis. This has led to a higher rate of early-stage Lyme disease diagnoses, fostering demand for diagnostic tests. Evidence of this can be observed in the decrease in cases diagnosed at later stages when the disease can be more challenging to treat.
Restraint of the lyme disease diagnostics market
While the lyme disease diagnostics market shows promise, a significant restraint is the limitations of current diagnostic methods, particularly in the early stages of the disease. Evidence of this challenge can be seen in cases where serological tests may yield false-negative results in the initial weeks after infection, as the patient's immune response may not have produced detectable antibodies. This diagnostic gap underscores the need for ongoing research and development efforts to enhance the sensitivity and specificity of early Lyme disease diagnostics, ensuring accurate detection and timely treatment.
Market Segmentation by Diagnostic Test (Serological Test, PCR Test, Others): Serological Tests Dominate the Market
In 2022, the highest revenue within the lyme disease diagnostics market was generated by serological tests, given their widespread use for Lyme disease screening. However, during the forecast period from 2023 to 2031, PCR tests are expected to exhibit the highest compound annual growth rate (CAGR). This growth is attributed to the increasing adoption of molecular diagnostic methods for Lyme disease, which offer greater sensitivity and specificity, particularly in the early stages of infection.
Market Segmentation by Sample (Blood, Cerebrospinal Fluid, Others): Blood Samples Dominate the Market
In 2022, blood samples accounted for the highest revenue within the lyme disease diagnostics market, as they are commonly used for serological and molecular diagnostic tests. However, during the forecast period from 2023 to 2031, cerebrospinal fluid samples are expected to experience the highest CAGR. This shift is driven by the growing recognition of neurological complications associated with Lyme disease, necessitating more frequent testing of cerebrospinal fluid for accurate diagnosis.
North America Remains as the Global Leader
Geographically, the lyme disease diagnostics market exhibits varying trends. North America, particularly the northeastern United States, has traditionally been a significant hotspot for Lyme disease cases. However, regions like Europe and parts of Asia are witnessing an increasing incidence of Lyme disease. These geographic trends are influenced by climate change, habitat changes, and increased awareness of the disease. The region with the highest revenue percentage in 2022 was North America, given its historical burden of Lyme disease cases. However, regions with emerging Lyme disease hotspots, such as parts of Europe, are expected to demonstrate the highest CAGR during the forecast period. These regions are experiencing a surge in reported cases and increased demand for Lyme disease diagnostics.
Innovation Remains as the Key to Enhane Market Share
The lyme disease diagnostics market is characterized by the presence of several key players who continually strive to innovate and provide accurate diagnostic solutions. Leading companies in this market include DiaSorin S.p.A, bioMA©rieux SA, Quidel Corporation, LabCorp, Quest Diagnostics, Abbott Laboratories, Bio-Rad Laboratories, Inc., DiaSorin S.p.A, T2 Biosystems, Inc., F. Hoffmann-La Roche AG, Meridian Bioscience, Inc., and Thermo Fisher Scientific Inc. Leading companies are investing in research and development to create novel diagnostic assays that improve the accuracy and specificity of Lyme disease diagnosis. These efforts include the development of advanced serological tests, PCR assays, and nucleic acid amplification techniques. Companies are expanding their geographic footprint by entering new markets and regions with an increasing incidence of Lyme disease. This expansion allows them to cater to a broader customer base and respond to the growing demand for diagnostic tests. Collaboration with research institutions, public health agencies, and healthcare providers is a strategic move for companies in the lyme disease diagnostics market. These partnerships facilitate the development of new diagnostic technologies and enhance market penetration. Leading players are actively engaged in awareness and educational initiatives to increase knowledge about Lyme disease and the importance of early diagnosis. These initiatives aim to empower both healthcare providers and the general public in recognizing and addressing the disease.
Historical & Forecast Period
This study report represents analysis of each segment from 2021 to 2031 considering 2022 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2023 to 2031.
The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.
Research Methodology
The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation ofLyme Disease Diagnostics market are as follows:
- Research and development budgets of manufacturers and government spending
- Revenues of key companies in the market segment
- Number of end users and consumption volume, price and value.
Geographical revenues generate by countries considered in the report:
Micro and macro environment factors that are currently influencing the Lyme Disease Diagnostics market and their expected impact during the forecast period.
Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.
Market Segmentation
Diagnostic Test
- Serological Test
- ELISA
- Western Blot
- Polymerase Chain Reaction (PCR) Test
- Others (Culture Test, Antigen Test, etc.)
Sample
- Blood
- Cerebrospinal Fluid (CSF)
- Others (Joint Fluid, Urine, etc.)
End-User
- Hospitals
- Diagnostic Laboratories
- Others (Clinics, Research Institutes, etc.)
Region Segment (2021-2031; US$ Million)
- North America
- U.S.
- Canada
- Rest of North America
- UK and European Union
- UK
- Germany
- Spain
- Italy
- France
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of Asia Pacific
- Latin America
- Brazil
- Mexico
- Rest of Latin America
- Middle East and Africa
- GCC
- Africa
- Rest of Middle East and Africa
Key questions answered in this report:
- What are the key micro and macro environmental factors that are impacting the growth of Lyme Disease Diagnostics market?
- What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?
- Estimated forecast and market projections up to 2031.
- Which segment accounts for the fastest CAGR during the forecast period?
- Which market segment holds a larger market share and why?
- Are low and middle-income economies investing in the Lyme Disease Diagnostics market?
- Which is the largest regional market for Lyme Disease Diagnostics market?
- What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
- Which are the key trends driving Lyme Disease Diagnostics market growth?
- Who are the key competitors and what are their key strategies to enhance their market presence in the Lyme Disease Diagnostics market worldwide?
Table of Contents
1. Preface
- 1.1. Report Description
- 1.1.1. Purpose of the Report
- 1.1.2. Target Audience
- 1.1.3. Key Offerings
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.3.1. Phase I - Secondary Research
- 1.3.2. Phase II - Primary Research
- 1.3.3. Phase III - Expert Panel Review
- 1.3.4. Assumptions
- 1.3.5. Approach Adopted
2. Executive Summary
- 2.1. Market Snapshot: Global Lyme Disease Diagnostics Market
- 2.2. Global Lyme Disease Diagnostics Market, By Diagnostic Test, 2022 (US$ Million)
- 2.3. Global Lyme Disease Diagnostics Market, By Sample, 2022 (US$ Million)
- 2.4. Global Lyme Disease Diagnostics Market, By End-User, 2022 (US$ Million)
- 2.5. Global Lyme Disease Diagnostics Market, By Geography, 2022 (US$ Million)
- 2.6. Attractive Investment Proposition by Geography, 2022
3. Lyme Disease Diagnostics Market: Competitive Analysis
- 3.1. Market Positioning of Key Lyme Disease Diagnostics Market Vendors
- 3.2. Strategies Adopted by Lyme Disease Diagnostics Market Vendors
- 3.3. Key Industry Strategies
- 3.4. Tier Analysis 2022 Versus 2031
4. Lyme Disease Diagnostics Market: Macro Analysis & Market Dynamics
- 4.1. Introduction
- 4.2. Global Lyme Disease Diagnostics Market Value, 2021 - 2031, (US$ Million)
- 4.3. Market Dynamics
- 4.3.1. Market Drivers
- 4.3.2. Market Restraints
- 4.3.3. Key Challenges
- 4.3.4. Key Opportunities
- 4.4. Impact Analysis of Drivers and Restraints
- 4.5. See-Saw Analysis
- 4.6. Porter's Five Force Model
- 4.6.1. Supplier Power
- 4.6.2. Buyer Power
- 4.6.3. Threat Of Substitutes
- 4.6.4. Threat Of New Entrants
- 4.6.5. Competitive Rivalry
- 4.7. PESTEL Analysis
- 4.7.1. Political Landscape
- 4.7.2. Economic Landscape
- 4.7.3. Technology Landscape
- 4.7.4. Legal Landscape
- 4.7.5. Social Landscape
5. Lyme Disease Diagnostics Market: By Diagnostic Test, 2021-2031, USD (Million)
- 5.1. Market Overview
- 5.2. Growth & Revenue Analysis: 2022 Versus 2031
- 5.3. Market Segmentation
- 5.3.1. Serological Test
- 5.3.1.1. ELISA
- 5.3.1.2. Western Blot
- 5.3.2. Polymerase Chain Reaction (PCR) Test
- 5.3.3. Others (Culture Test, Antigen Test, etc.)
- 5.3.1. Serological Test
6. Lyme Disease Diagnostics Market: By Sample, 2021-2031, USD (Million)
- 6.1. Market Overview
- 6.2. Growth & Revenue Analysis: 2022 Versus 2031
- 6.3. Market Segmentation
- 6.3.1. Blood
- 6.3.2. Cerebrospinal Fluid (CSF)
- 6.3.3. Others (Joint Fluid, Urine, etc.)
7. Lyme Disease Diagnostics Market: By End-User, 2021-2031, USD (Million)
- 7.1. Market Overview
- 7.2. Growth & Revenue Analysis: 2022 Versus 2031
- 7.3. Market Segmentation
- 7.3.1. Hospitals
- 7.3.2. Diagnostic Laboratories
- 7.3.3. Others (Clinics, Research Institutes, etc.)
8. North America Lyme Disease Diagnostics Market, 2021-2031, USD (Million)
- 8.1. Market Overview
- 8.2. Lyme Disease Diagnostics Market: By Diagnostic Test, 2021-2031, USD (Million)
- 8.3. Lyme Disease Diagnostics Market: By Sample, 2021-2031, USD (Million)
- 8.4. Lyme Disease Diagnostics Market: By End-User, 2021-2031, USD (Million)
- 8.5.Lyme Disease Diagnostics Market: By Region, 2021-2031, USD (Million)
- 8.5.1.North America
- 8.5.1.1. U.S.
- 8.5.1.1.1. Lyme Disease Diagnostics Market: By Diagnostic Test, 2021-2031, USD (Million)
- 8.5.1.1.2. Lyme Disease Diagnostics Market: By Sample, 2021-2031, USD (Million)
- 8.5.1.1.3. Lyme Disease Diagnostics Market: By End-User, 2021-2031, USD (Million)
- 8.5.1.2. Canada
- 8.5.1.2.1. Lyme Disease Diagnostics Market: By Diagnostic Test, 2021-2031, USD (Million)
- 8.5.1.2.2. Lyme Disease Diagnostics Market: By Sample, 2021-2031, USD (Million)
- 8.5.1.2.3. Lyme Disease Diagnostics Market: By End-User, 2021-2031, USD (Million)
- 8.5.1.3. Rest of North America
- 8.5.1.3.1. Lyme Disease Diagnostics Market: By Diagnostic Test, 2021-2031, USD (Million)
- 8.5.1.3.2. Lyme Disease Diagnostics Market: By Sample, 2021-2031, USD (Million)
- 8.5.1.3.3. Lyme Disease Diagnostics Market: By End-User, 2021-2031, USD (Million)
- 8.5.1.1. U.S.
- 8.5.1.North America
9. UK and European Union Lyme Disease Diagnostics Market, 2021-2031, USD (Million)
- 9.1. Market Overview
- 9.2. Lyme Disease Diagnostics Market: By Diagnostic Test, 2021-2031, USD (Million)
- 9.3. Lyme Disease Diagnostics Market: By Sample, 2021-2031, USD (Million)
- 9.4. Lyme Disease Diagnostics Market: By End-User, 2021-2031, USD (Million)
- 9.5.Lyme Disease Diagnostics Market: By Region, 2021-2031, USD (Million)
- 9.5.1.UK and European Union
- 9.5.1.1. UK
- 9.5.1.1.1. Lyme Disease Diagnostics Market: By Diagnostic Test, 2021-2031, USD (Million)
- 9.5.1.1.2. Lyme Disease Diagnostics Market: By Sample, 2021-2031, USD (Million)
- 9.5.1.1.3. Lyme Disease Diagnostics Market: By End-User, 2021-2031, USD (Million)
- 9.5.1.2. Germany
- 9.5.1.2.1. Lyme Disease Diagnostics Market: By Diagnostic Test, 2021-2031, USD (Million)
- 9.5.1.2.2. Lyme Disease Diagnostics Market: By Sample, 2021-2031, USD (Million)
- 9.5.1.2.3. Lyme Disease Diagnostics Market: By End-User, 2021-2031, USD (Million)
- 9.5.1.3. Spain
- 9.5.1.3.1. Lyme Disease Diagnostics Market: By Diagnostic Test, 2021-2031, USD (Million)
- 9.5.1.3.2. Lyme Disease Diagnostics Market: By Sample, 2021-2031, USD (Million)
- 9.5.1.3.3. Lyme Disease Diagnostics Market: By End-User, 2021-2031, USD (Million)
- 9.5.1.4. Italy
- 9.5.1.4.1. Lyme Disease Diagnostics Market: By Diagnostic Test, 2021-2031, USD (Million)
- 9.5.1.4.2. Lyme Disease Diagnostics Market: By Sample, 2021-2031, USD (Million)
- 9.5.1.4.3. Lyme Disease Diagnostics Market: By End-User, 2021-2031, USD (Million)
- 9.5.1.5. France
- 9.5.1.5.1. Lyme Disease Diagnostics Market: By Diagnostic Test, 2021-2031, USD (Million)
- 9.5.1.5.2. Lyme Disease Diagnostics Market: By Sample, 2021-2031, USD (Million)
- 9.5.1.5.3. Lyme Disease Diagnostics Market: By End-User, 2021-2031, USD (Million)
- 9.5.1.6. Rest of Europe
- 9.5.1.6.1. Lyme Disease Diagnostics Market: By Diagnostic Test, 2021-2031, USD (Million)
- 9.5.1.6.2. Lyme Disease Diagnostics Market: By Sample, 2021-2031, USD (Million)
- 9.5.1.6.3. Lyme Disease Diagnostics Market: By End-User, 2021-2031, USD (Million)
- 9.5.1.1. UK
- 9.5.1.UK and European Union
10. Asia Pacific Lyme Disease Diagnostics Market, 2021-2031, USD (Million)
- 10.1. Market Overview
- 10.2. Lyme Disease Diagnostics Market: By Diagnostic Test, 2021-2031, USD (Million)
- 10.3. Lyme Disease Diagnostics Market: By Sample, 2021-2031, USD (Million)
- 10.4. Lyme Disease Diagnostics Market: By End-User, 2021-2031, USD (Million)
- 10.5.Lyme Disease Diagnostics Market: By Region, 2021-2031, USD (Million)
- 10.5.1.Asia Pacific
- 10.5.1.1. China
- 10.5.1.1.1. Lyme Disease Diagnostics Market: By Diagnostic Test, 2021-2031, USD (Million)
- 10.5.1.1.2. Lyme Disease Diagnostics Market: By Sample, 2021-2031, USD (Million)
- 10.5.1.1.3. Lyme Disease Diagnostics Market: By End-User, 2021-2031, USD (Million)
- 10.5.1.2. Japan
- 10.5.1.2.1. Lyme Disease Diagnostics Market: By Diagnostic Test, 2021-2031, USD (Million)
- 10.5.1.2.2. Lyme Disease Diagnostics Market: By Sample, 2021-2031, USD (Million)
- 10.5.1.2.3. Lyme Disease Diagnostics Market: By End-User, 2021-2031, USD (Million)
- 10.5.1.3. India
- 10.5.1.3.1. Lyme Disease Diagnostics Market: By Diagnostic Test, 2021-2031, USD (Million)
- 10.5.1.3.2. Lyme Disease Diagnostics Market: By Sample, 2021-2031, USD (Million)
- 10.5.1.3.3. Lyme Disease Diagnostics Market: By End-User, 2021-2031, USD (Million)
- 10.5.1.4. Australia
- 10.5.1.4.1. Lyme Disease Diagnostics Market: By Diagnostic Test, 2021-2031, USD (Million)
- 10.5.1.4.2. Lyme Disease Diagnostics Market: By Sample, 2021-2031, USD (Million)
- 10.5.1.4.3. Lyme Disease Diagnostics Market: By End-User, 2021-2031, USD (Million)
- 10.5.1.5. South Korea
- 10.5.1.5.1. Lyme Disease Diagnostics Market: By Diagnostic Test, 2021-2031, USD (Million)
- 10.5.1.5.2. Lyme Disease Diagnostics Market: By Sample, 2021-2031, USD (Million)
- 10.5.1.5.3. Lyme Disease Diagnostics Market: By End-User, 2021-2031, USD (Million)
- 10.5.1.6. Rest of Asia Pacific
- 10.5.1.6.1. Lyme Disease Diagnostics Market: By Diagnostic Test, 2021-2031, USD (Million)
- 10.5.1.6.2. Lyme Disease Diagnostics Market: By Sample, 2021-2031, USD (Million)
- 10.5.1.6.3. Lyme Disease Diagnostics Market: By End-User, 2021-2031, USD (Million)
- 10.5.1.1. China
- 10.5.1.Asia Pacific
11. Latin America Lyme Disease Diagnostics Market, 2021-2031, USD (Million)
- 11.1. Market Overview
- 11.2. Lyme Disease Diagnostics Market: By Diagnostic Test, 2021-2031, USD (Million)
- 11.3. Lyme Disease Diagnostics Market: By Sample, 2021-2031, USD (Million)
- 11.4. Lyme Disease Diagnostics Market: By End-User, 2021-2031, USD (Million)
- 11.5.Lyme Disease Diagnostics Market: By Region, 2021-2031, USD (Million)
- 11.5.1.Latin America
- 11.5.1.1. Brazil
- 11.5.1.1.1. Lyme Disease Diagnostics Market: By Diagnostic Test, 2021-2031, USD (Million)
- 11.5.1.1.2. Lyme Disease Diagnostics Market: By Sample, 2021-2031, USD (Million)
- 11.5.1.1.3. Lyme Disease Diagnostics Market: By End-User, 2021-2031, USD (Million)
- 11.5.1.2. Mexico
- 11.5.1.2.1. Lyme Disease Diagnostics Market: By Diagnostic Test, 2021-2031, USD (Million)
- 11.5.1.2.2. Lyme Disease Diagnostics Market: By Sample, 2021-2031, USD (Million)
- 11.5.1.2.3. Lyme Disease Diagnostics Market: By End-User, 2021-2031, USD (Million)
- 11.5.1.3. Rest of Latin America
- 11.5.1.3.1. Lyme Disease Diagnostics Market: By Diagnostic Test, 2021-2031, USD (Million)
- 11.5.1.3.2. Lyme Disease Diagnostics Market: By Sample, 2021-2031, USD (Million)
- 11.5.1.3.3. Lyme Disease Diagnostics Market: By End-User, 2021-2031, USD (Million)
- 11.5.1.1. Brazil
- 11.5.1.Latin America
12. Middle East and Africa Lyme Disease Diagnostics Market, 2021-2031, USD (Million)
- 12.1. Market Overview
- 12.2. Lyme Disease Diagnostics Market: By Diagnostic Test, 2021-2031, USD (Million)
- 12.3. Lyme Disease Diagnostics Market: By Sample, 2021-2031, USD (Million)
- 12.4. Lyme Disease Diagnostics Market: By End-User, 2021-2031, USD (Million)
- 12.5.Lyme Disease Diagnostics Market: By Region, 2021-2031, USD (Million)
- 12.5.1.Middle East and Africa
- 12.5.1.1. GCC
- 12.5.1.1.1. Lyme Disease Diagnostics Market: By Diagnostic Test, 2021-2031, USD (Million)
- 12.5.1.1.2. Lyme Disease Diagnostics Market: By Sample, 2021-2031, USD (Million)
- 12.5.1.1.3. Lyme Disease Diagnostics Market: By End-User, 2021-2031, USD (Million)
- 12.5.1.2. Africa
- 12.5.1.2.1. Lyme Disease Diagnostics Market: By Diagnostic Test, 2021-2031, USD (Million)
- 12.5.1.2.2. Lyme Disease Diagnostics Market: By Sample, 2021-2031, USD (Million)
- 12.5.1.2.3. Lyme Disease Diagnostics Market: By End-User, 2021-2031, USD (Million)
- 12.5.1.3. Rest of Middle East and Africa
- 12.5.1.3.1. Lyme Disease Diagnostics Market: By Diagnostic Test, 2021-2031, USD (Million)
- 12.5.1.3.2. Lyme Disease Diagnostics Market: By Sample, 2021-2031, USD (Million)
- 12.5.1.3.3. Lyme Disease Diagnostics Market: By End-User, 2021-2031, USD (Million)
- 12.5.1.1. GCC
- 12.5.1.Middle East and Africa
13. Company Profile
- 13.1. DiaSorin S.p.A
- 13.1.1. Company Overview
- 13.1.2. Financial Performance
- 13.1.3. Product Portfolio
- 13.1.4. Strategic Initiatives
- 13.2. bioMerieux SA
- 13.2.1. Company Overview
- 13.2.2. Financial Performance
- 13.2.3. Product Portfolio
- 13.2.4. Strategic Initiatives
- 13.3. Quidel Corporation
- 13.3.1. Company Overview
- 13.3.2. Financial Performance
- 13.3.3. Product Portfolio
- 13.3.4. Strategic Initiatives
- 13.4. LabCorp
- 13.4.1. Company Overview
- 13.4.2. Financial Performance
- 13.4.3. Product Portfolio
- 13.4.4. Strategic Initiatives
- 13.5. Quest Diagnostics
- 13.5.1. Company Overview
- 13.5.2. Financial Performance
- 13.5.3. Product Portfolio
- 13.5.4. Strategic Initiatives
- 13.6. Abbott Laboratories
- 13.6.1. Company Overview
- 13.6.2. Financial Performance
- 13.6.3. Product Portfolio
- 13.6.4. Strategic Initiatives
- 13.7. Bio-Rad Laboratories, Inc.
- 13.7.1. Company Overview
- 13.7.2. Financial Performance
- 13.7.3. Product Portfolio
- 13.7.4. Strategic Initiatives
- 13.8. DiaSorin S.p.A
- 13.8.1. Company Overview
- 13.8.2. Financial Performance
- 13.8.3. Product Portfolio
- 13.8.4. Strategic Initiatives
- 13.9. T2 Biosystems, Inc.
- 13.9.1. Company Overview
- 13.9.2. Financial Performance
- 13.9.3. Product Portfolio
- 13.9.4. Strategic Initiatives
- 13.10. F. Hoffmann-La Roche AG
- 13.10.1. Company Overview
- 13.10.2. Financial Performance
- 13.10.3. Product Portfolio
- 13.10.4. Strategic Initiatives
- 13.11. Meridian Bioscience, Inc.
- 13.11.1. Company Overview
- 13.11.2. Financial Performance
- 13.11.3. Product Portfolio
- 13.11.4. Strategic Initiatives
- 13.12. Thermo Fisher Scientific Inc.
- 13.12.1. Company Overview
- 13.12.2. Financial Performance
- 13.12.3. Product Portfolio
- 13.12.4. Strategic Initiatives
- 13.13. Other Notable Players
- 13.13.1. Company Overview
- 13.13.2. Financial Performance
- 13.13.3. Product Portfolio
- 13.13.4. Strategic Initiatives
List of Tables
- TABLE 1 Global Lyme Disease Diagnostics Market By Diagnostic Test, 2021-2031, USD (Million)
- TABLE 2 Global Lyme Disease Diagnostics Market By Serological Test, 2021-2031, USD (Million)
TABLE 3 Global Lyme Disease Diagnostics Market By Sample, 2021-2031, USD (Million)
- TABLE 4 Global Lyme Disease Diagnostics Market By End-User, 2021-2031, USD (Million)
- TABLE 5 North America Lyme Disease Diagnostics Market By Diagnostic Test, 2021-2031, USD (Million)
- TABLE 6 North America Lyme Disease Diagnostics Market By Serological Test, 2021-2031, USD (Million)
TABLE 7 North America Lyme Disease Diagnostics Market By Sample, 2021-2031, USD (Million)
- TABLE 8 North America Lyme Disease Diagnostics Market By End-User, 2021-2031, USD (Million)
- TABLE 9 U.S. Lyme Disease Diagnostics Market By Diagnostic Test, 2021-2031, USD (Million)
- TABLE 10 U.S. Lyme Disease Diagnostics Market By Serological Test, 2021-2031, USD (Million)
TABLE 11 U.S. Lyme Disease Diagnostics Market By Sample, 2021-2031, USD (Million)
- TABLE 12 U.S. Lyme Disease Diagnostics Market By End-User, 2021-2031, USD (Million)
- TABLE 13 Canada Lyme Disease Diagnostics Market By Diagnostic Test, 2021-2031, USD (Million)
- TABLE 14 Canada Lyme Disease Diagnostics Market By Serological Test, 2021-2031, USD (Million)
TABLE 15 Canada Lyme Disease Diagnostics Market By Sample, 2021-2031, USD (Million)
- TABLE 16 Canada Lyme Disease Diagnostics Market By End-User, 2021-2031, USD (Million)
- TABLE 17 Rest of North America Lyme Disease Diagnostics Market By Diagnostic Test, 2021-2031, USD (Million)
- TABLE 18 Rest of North America Lyme Disease Diagnostics Market By Serological Test, 2021-2031, USD (Million)
TABLE 19 Rest of North America Lyme Disease Diagnostics Market By Sample, 2021-2031, USD (Million)
- TABLE 20 Rest of North America Lyme Disease Diagnostics Market By End-User, 2021-2031, USD (Million)
- TABLE 21 UK and European Union Lyme Disease Diagnostics Market By Diagnostic Test, 2021-2031, USD (Million)
- TABLE 22 UK and European Union Lyme Disease Diagnostics Market By Serological Test, 2021-2031, USD (Million)
TABLE 23 UK and European Union Lyme Disease Diagnostics Market By Sample, 2021-2031, USD (Million)
- TABLE 24 UK and European Union Lyme Disease Diagnostics Market By End-User, 2021-2031, USD (Million)
- TABLE 25 UK Lyme Disease Diagnostics Market By Diagnostic Test, 2021-2031, USD (Million)
- TABLE 26 UK Lyme Disease Diagnostics Market By Serological Test, 2021-2031, USD (Million)
TABLE 27 UK Lyme Disease Diagnostics Market By Sample, 2021-2031, USD (Million)
- TABLE 28 UK Lyme Disease Diagnostics Market By End-User, 2021-2031, USD (Million)
- TABLE 29 Germany Lyme Disease Diagnostics Market By Diagnostic Test, 2021-2031, USD (Million)
- TABLE 30 Germany Lyme Disease Diagnostics Market By Serological Test, 2021-2031, USD (Million)
TABLE 31 Germany Lyme Disease Diagnostics Market By Sample, 2021-2031, USD (Million)
- TABLE 32 Germany Lyme Disease Diagnostics Market By End-User, 2021-2031, USD (Million)
- TABLE 33 Spain Lyme Disease Diagnostics Market By Diagnostic Test, 2021-2031, USD (Million)
- TABLE 34 Spain Lyme Disease Diagnostics Market By Serological Test, 2021-2031, USD (Million)
TABLE 35 Spain Lyme Disease Diagnostics Market By Sample, 2021-2031, USD (Million)
- TABLE 36 Spain Lyme Disease Diagnostics Market By End-User, 2021-2031, USD (Million)
- TABLE 37 Italy Lyme Disease Diagnostics Market By Diagnostic Test, 2021-2031, USD (Million)
- TABLE 38 Italy Lyme Disease Diagnostics Market By Serological Test, 2021-2031, USD (Million)
TABLE 39 Italy Lyme Disease Diagnostics Market By Sample, 2021-2031, USD (Million)
- TABLE 40 Italy Lyme Disease Diagnostics Market By End-User, 2021-2031, USD (Million)
- TABLE 41 France Lyme Disease Diagnostics Market By Diagnostic Test, 2021-2031, USD (Million)
- TABLE 42 France Lyme Disease Diagnostics Market By Serological Test, 2021-2031, USD (Million)
TABLE 43 France Lyme Disease Diagnostics Market By Sample, 2021-2031, USD (Million)
- TABLE 44 France Lyme Disease Diagnostics Market By End-User, 2021-2031, USD (Million)
- TABLE 45 Rest of Europe Lyme Disease Diagnostics Market By Diagnostic Test, 2021-2031, USD (Million)
- TABLE 46 Rest of Europe Lyme Disease Diagnostics Market By Serological Test, 2021-2031, USD (Million)
TABLE 47 Rest of Europe Lyme Disease Diagnostics Market By Sample, 2021-2031, USD (Million)
- TABLE 48 Rest of Europe Lyme Disease Diagnostics Market By End-User, 2021-2031, USD (Million)
- TABLE 49 Asia Lyme Disease Diagnostics Market By Diagnostic Test, 2021-2031, USD (Million)
- TABLE 50 Asia Lyme Disease Diagnostics Market By Serological Test, 2021-2031, USD (Million)
TABLE 51 Asia Lyme Disease Diagnostics Market By Sample, 2021-2031, USD (Million)
- TABLE 52 Asia Lyme Disease Diagnostics Market By End-User, 2021-2031, USD (Million)
- TABLE 53 China Lyme Disease Diagnostics Market By Diagnostic Test, 2021-2031, USD (Million)
- TABLE 54 China Lyme Disease Diagnostics Market By Serological Test, 2021-2031, USD (Million)
TABLE 55 China Lyme Disease Diagnostics Market By Sample, 2021-2031, USD (Million)
- TABLE 56 China Lyme Disease Diagnostics Market By End-User, 2021-2031, USD (Million)
- TABLE 57 Japan Lyme Disease Diagnostics Market By Diagnostic Test, 2021-2031, USD (Million)
- TABLE 58 Japan Lyme Disease Diagnostics Market By Serological Test, 2021-2031, USD (Million)
TABLE 59 Japan Lyme Disease Diagnostics Market By Sample, 2021-2031, USD (Million)
- TABLE 60 Japan Lyme Disease Diagnostics Market By End-User, 2021-2031, USD (Million)
- TABLE 61 India Lyme Disease Diagnostics Market By Diagnostic Test, 2021-2031, USD (Million)
- TABLE 62 India Lyme Disease Diagnostics Market By Serological Test, 2021-2031, USD (Million)
TABLE 63 India Lyme Disease Diagnostics Market By Sample, 2021-2031, USD (Million)
- TABLE 64 India Lyme Disease Diagnostics Market By End-User, 2021-2031, USD (Million)
- TABLE 65 Australia Lyme Disease Diagnostics Market By Diagnostic Test, 2021-2031, USD (Million)
- TABLE 66 Australia Lyme Disease Diagnostics Market By Serological Test, 2021-2031, USD (Million)
TABLE 67 Australia Lyme Disease Diagnostics Market By Sample, 2021-2031, USD (Million)
- TABLE 68 Australia Lyme Disease Diagnostics Market By End-User, 2021-2031, USD (Million)
- TABLE 69 South Korea Lyme Disease Diagnostics Market By Diagnostic Test, 2021-2031, USD (Million)
- TABLE 70 South Korea Lyme Disease Diagnostics Market By Serological Test, 2021-2031, USD (Million)
TABLE 71 South Korea Lyme Disease Diagnostics Market By Sample, 2021-2031, USD (Million)
- TABLE 72 South Korea Lyme Disease Diagnostics Market By End-User, 2021-2031, USD (Million)
- TABLE 73 Latin America Lyme Disease Diagnostics Market By Diagnostic Test, 2021-2031, USD (Million)
- TABLE 74 Latin America Lyme Disease Diagnostics Market By Serological Test, 2021-2031, USD (Million)
TABLE 75 Latin America Lyme Disease Diagnostics Market By Sample, 2021-2031, USD (Million)
- TABLE 76 Latin America Lyme Disease Diagnostics Market By End-User, 2021-2031, USD (Million)
- TABLE 77 Brazil Lyme Disease Diagnostics Market By Diagnostic Test, 2021-2031, USD (Million)
- TABLE 78 Brazil Lyme Disease Diagnostics Market By Serological Test, 2021-2031, USD (Million)
TABLE 79 Brazil Lyme Disease Diagnostics Market By Sample, 2021-2031, USD (Million)
- TABLE 80 Brazil Lyme Disease Diagnostics Market By End-User, 2021-2031, USD (Million)
- TABLE 81 Mexico Lyme Disease Diagnostics Market By Diagnostic Test, 2021-2031, USD (Million)
- TABLE 82 Mexico Lyme Disease Diagnostics Market By Serological Test, 2021-2031, USD (Million)
TABLE 83 Mexico Lyme Disease Diagnostics Market By Sample, 2021-2031, USD (Million)
- TABLE 84 Mexico Lyme Disease Diagnostics Market By End-User, 2021-2031, USD (Million)
- TABLE 85 Rest of Latin America Lyme Disease Diagnostics Market By Diagnostic Test, 2021-2031, USD (Million)
- TABLE 86 Rest of Latin America Lyme Disease Diagnostics Market By Serological Test, 2021-2031, USD (Million)
TABLE 87 Rest of Latin America Lyme Disease Diagnostics Market By Sample, 2021-2031, USD (Million)
- TABLE 88 Rest of Latin America Lyme Disease Diagnostics Market By End-User, 2021-2031, USD (Million)
- TABLE 89 Middle East and Africa Lyme Disease Diagnostics Market By Diagnostic Test, 2021-2031, USD (Million)
- TABLE 90 Middle East and Africa Lyme Disease Diagnostics Market By Serological Test, 2021-2031, USD (Million)
TABLE 91 Middle East and Africa Lyme Disease Diagnostics Market By Sample, 2021-2031, USD (Million)
- TABLE 92 Middle East and Africa Lyme Disease Diagnostics Market By End-User, 2021-2031, USD (Million)
- TABLE 93 GCC Lyme Disease Diagnostics Market By Diagnostic Test, 2021-2031, USD (Million)
- TABLE 94 GCC Lyme Disease Diagnostics Market By Serological Test, 2021-2031, USD (Million)
TABLE 95 GCC Lyme Disease Diagnostics Market By Sample, 2021-2031, USD (Million)
- TABLE 96 GCC Lyme Disease Diagnostics Market By End-User, 2021-2031, USD (Million)
- TABLE 97 Africa Lyme Disease Diagnostics Market By Diagnostic Test, 2021-2031, USD (Million)
- TABLE 98 Africa Lyme Disease Diagnostics Market By Serological Test, 2021-2031, USD (Million)
TABLE 99 Africa Lyme Disease Diagnostics Market By Sample, 2021-2031, USD (Million)
- TABLE 100 Africa Lyme Disease Diagnostics Market By End-User, 2021-2031, USD (Million)
- TABLE 101 Rest of Middle East and Africa Lyme Disease Diagnostics Market By Diagnostic Test, 2021-2031, USD (Million)
- TABLE 102 Rest of Middle East and Africa Lyme Disease Diagnostics Market By Serological Test, 2021-2031, USD (Million)
TABLE 103 Rest of Middle East and Africa Lyme Disease Diagnostics Market By Sample, 2021-2031, USD (Million)
- TABLE 104 Rest of Middle East and Africa Lyme Disease Diagnostics Market By End-User, 2021-2031, USD (Million)
List of Figures
- FIG. 1 Global Lyme Disease Diagnostics Market: Market Coverage
- FIG. 2 Research Methodology and Data Sources
- FIG. 3 Market Size Estimation - Top Down & Bottom-Up Approach
- FIG. 4 Global Lyme Disease Diagnostics Market: Quality Assurance
- FIG. 5 Global Lyme Disease Diagnostics Market, By Diagnostic Test, 2022
- FIG. 6 Global Lyme Disease Diagnostics Market, By Sample, 2022
- FIG. 7 Global Lyme Disease Diagnostics Market, By End-User, 2022
- FIG. 8 Global Lyme Disease Diagnostics Market, By Geography, 2022
- FIG. 9 Market Geographical Opportunity Matrix - Global Lyme Disease Diagnostics Market, 2022
FIG. 10Market Positioning of Key Lyme Disease Diagnostics Market Players, 2022
FIG. 11Global Lyme Disease Diagnostics Market - Tier Analysis - Percentage of Revenues by Tier Level, 2022 Versus 2031
- FIG. 12 Global Lyme Disease Diagnostics Market, By Diagnostic Test, 2022 Vs 2031, %
- FIG. 13 Global Lyme Disease Diagnostics Market, By Sample, 2022 Vs 2031, %
- FIG. 14 Global Lyme Disease Diagnostics Market, By End-User, 2022 Vs 2031, %
- FIG. 15 U.S. Lyme Disease Diagnostics Market (US$ Million), 2021 - 2031
- FIG. 16 Canada Lyme Disease Diagnostics Market (US$ Million), 2021 - 2031
- FIG. 17 Rest of North America Lyme Disease Diagnostics Market (US$ Million), 2021 - 2031
- FIG. 18 UK Lyme Disease Diagnostics Market (US$ Million), 2021 - 2031
- FIG. 19 Germany Lyme Disease Diagnostics Market (US$ Million), 2021 - 2031
- FIG. 20 Spain Lyme Disease Diagnostics Market (US$ Million), 2021 - 2031
- FIG. 21 Italy Lyme Disease Diagnostics Market (US$ Million), 2021 - 2031
- FIG. 22 France Lyme Disease Diagnostics Market (US$ Million), 2021 - 2031
- FIG. 23 Rest of Europe Lyme Disease Diagnostics Market (US$ Million), 2021 - 2031
- FIG. 24 China Lyme Disease Diagnostics Market (US$ Million), 2021 - 2031
- FIG. 25 Japan Lyme Disease Diagnostics Market (US$ Million), 2021 - 2031
- FIG. 26 India Lyme Disease Diagnostics Market (US$ Million), 2021 - 2031
- FIG. 27 Australia Lyme Disease Diagnostics Market (US$ Million), 2021 - 2031
- FIG. 28 South Korea Lyme Disease Diagnostics Market (US$ Million), 2021 - 2031
- FIG. 29 Rest of Asia Lyme Disease Diagnostics Market (US$ Million), 2021 - 2031
- FIG. 30 Brazil Lyme Disease Diagnostics Market (US$ Million), 2021 - 2031
- FIG. 31 Mexico Lyme Disease Diagnostics Market (US$ Million), 2021 - 2031
- FIG. 32 Rest of Latin America Lyme Disease Diagnostics Market (US$ Million), 2021 - 2031
- FIG. 33 GCC Lyme Disease Diagnostics Market (US$ Million), 2021 - 2031
- FIG. 34 Africa Lyme Disease Diagnostics Market (US$ Million), 2021 - 2031
- FIG. 35 Rest of Middle East and Africa Lyme Disease Diagnostics Market (US$ Million), 2021 - 2031
